| Ms Karin Kristen Phillips, CRNA | |
|
7103 Fairway Dr, Palm Beach Gardens, FL 33418-3701 | |
| (561) 355-8505 | |
| (561) 355-8555 |
| Full Name | Ms Karin Kristen Phillips |
|---|---|
| Gender | Female |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 7103 Fairway Dr, Palm Beach Gardens, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134389554 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | ANT3348512 (Florida) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | ARNP3348512 (Florida) | Primary |
| Entity Name | Sheridan Healthcorp Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629781711 PECOS PAC ID: 3173429693 Enrollment ID: O20031208000355 |
News Archive
Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year's Go Red for Women® special issue of the American Heart Association's flagship journal Circulation, published online today.
A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun.
Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.
› Verified 9 days ago
| Entity Name | Jupiter Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700073848 PECOS PAC ID: 0547348211 Enrollment ID: O20080421000429 |
News Archive
Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year's Go Red for Women® special issue of the American Heart Association's flagship journal Circulation, published online today.
A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun.
Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.
› Verified 9 days ago
| Entity Name | St Lucie Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700044252 PECOS PAC ID: 4284792706 Enrollment ID: O20081027000765 |
News Archive
Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year's Go Red for Women® special issue of the American Heart Association's flagship journal Circulation, published online today.
A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun.
Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.
› Verified 9 days ago
| Entity Name | Pbg Team Anesthesia Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861623316 PECOS PAC ID: 5092856757 Enrollment ID: O20100104000521 |
News Archive
Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year's Go Red for Women® special issue of the American Heart Association's flagship journal Circulation, published online today.
A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun.
Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.
› Verified 9 days ago
| Entity Name | Ocala Anesthesia Ams Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699197343 PECOS PAC ID: 4789814617 Enrollment ID: O20140220000864 |
News Archive
Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year's Go Red for Women® special issue of the American Heart Association's flagship journal Circulation, published online today.
A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun.
Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.
› Verified 9 days ago
| Entity Name | Ams National Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316330830 PECOS PAC ID: 3870813025 Enrollment ID: O20150529000613 |
News Archive
Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year's Go Red for Women® special issue of the American Heart Association's flagship journal Circulation, published online today.
A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun.
Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Karin Kristen Phillips, CRNA 7103 Fairway Dr, Palm Beach Gardens, FL 33418-3701 Ph: (561) 355-8505 | Ms Karin Kristen Phillips, CRNA 7103 Fairway Dr, Palm Beach Gardens, FL 33418-3701 Ph: (561) 355-8505 |
News Archive
Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year's Go Red for Women® special issue of the American Heart Association's flagship journal Circulation, published online today.
A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun.
Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.
› Verified 9 days ago
Emily M. Nazworth, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 7111 Fairway Drive, Suite 450, Palmetto Anesthesia Specialists, Llc, Palm Beach Gardens, FL 33418 Phone: 561-799-3552 Fax: 561-799-3527 | |
Mark W Chiampou, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3360 Burns Rd, Palm Beach Gardens, FL 33410 Phone: 561-622-1411 | |
Jennifer Lynn Havenstein, CRNA, MS Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7103 Fairway Dr, Palm Beach Gardens, FL 33418 Phone: 561-515-1500 Fax: 561-515-1513 | |
Keith Peart, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3360 Burns Road, Palm Beach Gardens, FL 33410 Phone: 561-622-1411 | |
Courtney Gallo, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3360 Burns Rd, Palm Beach Gardens, FL 33410 Phone: 561-622-1411 | |
Tunde Birtok, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7103 Fairway Dr, Palm Beach Gardens, FL 33418 Phone: 561-355-8505 | |
John Cannova Jr., CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3360 Burns Rd, Palm Beach Gardens, FL 33410 Phone: 561-626-9882 Fax: 561-626-5811 |